Evaluation of Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 with Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Patients

The primary objective of this study is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **efficacy** of RO7443904 in combination with glofitamab in participants with **relapsed/refractory B-Cell Non-Hodgkin’s Lymphoma**. This is clinically relevant as it aims to address the therapeutic needs of patients with this challenging condition, potentially offering new treatment options for those who have not responded to or have relapsed after standard therapies.

The clinical trial involves a total of **96 participants** diagnosed with **Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)**. The study population includes both male and female subjects, with an age range that spans from young adults to older adults. Participants were selected to include a vulnerable population, although specific selection criteria have not been disclosed by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The general health status of the participants is not detailed, and no additional key inclusion or exclusion criteria have been provided.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and efficacy of RO7443904 in combination with glofitamab in participants with **relapsed/refractory B-cell non-Hodgkin's lymphoma**. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date was March 25, 2022, with an anticipated end date of April 30, 2025. The trial involves a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants who meet the inclusion criteria will be randomized to receive either the investigational treatment or a control. Follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, assess any adverse events, and ensure compliance with the study protocol. The end-of-study visit will occur after the completion of the treatment period, where final assessments will be conducted to evaluate the primary and secondary endpoints. The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to last until the end of the study period. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or non-compliance with the study protocol. Participants will be closely monitored throughout the trial to ensure their safety and the integrity of the study data.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to have an estimated recruitment start date of March 25, 2022, and an estimated end date of April 30, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints used to evaluate efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The methodology for measuring and analyzing efficacy will be aligned with the trial's objectives, ensuring that the results are scientifically valid and reliable. The trial's design will incorporate appropriate tools and instruments to facilitate accurate efficacy assessments, although specific tools are not mentioned in the available information.